Positive Mismatch 4QFY19E; HOLD With Higher Target Price
Sequential earnings could improve substantially on higher latex glove ASPs and seasonally lower latex costs. Although we maintain our forecasts, we raise our Target Price by 9% to MYR4.85 on a higher CY20E P/E target P/E of 26x from 24x; This is in view of its rising margin/ROE prospects due to Aspion’s surgical gloves and inclusion in FBMKLCI 30 since Dec 2018.
Our new target is still 10% below our 29x target for Hartalega due to TOP GLOVE’s lower margins/ROEs.
Maintain HOLD as we believe its positives have been priced in.
Stronger Earnings Ahead
Top Glove's 3QFY19 net profit, down 29% q-o-q and 37% y-o-y, was hit by high latex costs and intense competition. However, we expect earnings to improve substantially in 4QFY19E as latex-glove ASPs have already been raised to reflect the higher latex costs while latex costs are expected to be seasonally lower.
Additionally, new capacity from F32-33 (+6% to 63.9b pcs in Jun 2019) may lift sales volumes. Plant utilisation is high at 90%, excluding F32-33.
Delays to Plant Expansion
Expansion of another eight plants has been delayed by 3-6 months. Management attributes this to delays in construction and gas-supply issues.
Separately, Top Glove recently launched its new nitrile biodegradable glove which could yield better margins as its ASP is 10% above those of normal examination gloves.
Our earnings model assumes sales volume growth of 14%/11%/11% for FY19-21E.
Limited Benefits From US Trade Tiff
We think Top Glove may not benefit much from a potential 25% tariff on China’s medical gloves. Top Glove has a bigger presence in non-US markets, which may be disrupted if China diverts its gloves from the US to these markets.
It may also not benefit much from a potential removal of Thailand/Indonesia from the US GSP list.
Non-medical rubber gloves produced by Top Glove’s factories in Malaysia are not substantial, at < 10% of its sales volume.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....